Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
© 2023. The Author(s)..
INTRODUCTION: Vaccination is a critical tool for preventing coronavirus disease 2019 (COVID-19) and influenza illnesses. Coadministration of the COVID-19 vaccine, BNT162b2, with seasonal inactivated influenza vaccine (SIIV) can provide substantial benefits, including streamlining vaccine delivery.
METHODS: In this phase 3 study, healthy 18- to 64-year-olds who had received three previous doses of BNT162b2 were randomized (1:1) to the coadministration group (month 0, BNT162b2 + SIIV; month 1, placebo) or the separate-administration group (month 0, placebo + SIIV; month 1, BNT162b2). The primary immunogenicity objective was to demonstrate that the immune responses elicited by BNT162b2 and SIIV [measured by full-length S-binding immunoglobulin G (IgG) levels and strain-specific hemagglutination inhibition assay (HAI) titers against four influenza strains 1 month post-vaccination, respectively] when coadministered were noninferior to those elicited by either vaccine administered alone, based on a prespecified 1.5-fold noninferiority margin [lower bound 95% CI for geometric mean ratio (GMR) > 0.67]. Reactogenicity and adverse event (AE) rates were evaluated.
RESULTS: Randomized participants who received study vaccination (N = 1128; coadministration group, n = 564; separate-administration group, n = 564) had a median age of 39 years. Model-adjusted GMRs for coadministration to separate administration were 0.83 (95% CI 0.77, 0.89) for full-length S-binding IgG levels and 0.89-1.00 (lower bound of all 95% CIs > 0.67) for the four influenza strain-specific HAI titers, with all endpoints achieving the prespecified noninferiority criterion. Reactogenicity events were mostly mild or moderate when BNT162b2 was coadministered with SIIV. Serious AEs were reported in < 1% of participants within 1 month after any vaccination; none were considered vaccine-related.
CONCLUSIONS: BNT162b2 coadministered with SIIV elicited immune responses that were noninferior to those elicited by BNT162b2 alone and SIIV alone, and BNT162b2 had an acceptable safety profile when coadministered with SIIV. The results of this study support the coadministration of BNT162b2 and SIIV in adults.
TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT05310084.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 12(2023), 9 vom: 12. Sept., Seite 2241-2258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murdoch, Louise [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162b2 |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic ClinicalTrials.gov: NCT05310084 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-023-00863-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36196160X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36196160X | ||
| 003 | DE-627 | ||
| 005 | 20231226090240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-023-00863-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM36196160X | ||
| 035 | |a (NLM)37698774 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murdoch, Louise |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05310084 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Vaccination is a critical tool for preventing coronavirus disease 2019 (COVID-19) and influenza illnesses. Coadministration of the COVID-19 vaccine, BNT162b2, with seasonal inactivated influenza vaccine (SIIV) can provide substantial benefits, including streamlining vaccine delivery | ||
| 520 | |a METHODS: In this phase 3 study, healthy 18- to 64-year-olds who had received three previous doses of BNT162b2 were randomized (1:1) to the coadministration group (month 0, BNT162b2 + SIIV; month 1, placebo) or the separate-administration group (month 0, placebo + SIIV; month 1, BNT162b2). The primary immunogenicity objective was to demonstrate that the immune responses elicited by BNT162b2 and SIIV [measured by full-length S-binding immunoglobulin G (IgG) levels and strain-specific hemagglutination inhibition assay (HAI) titers against four influenza strains 1 month post-vaccination, respectively] when coadministered were noninferior to those elicited by either vaccine administered alone, based on a prespecified 1.5-fold noninferiority margin [lower bound 95% CI for geometric mean ratio (GMR) > 0.67]. Reactogenicity and adverse event (AE) rates were evaluated | ||
| 520 | |a RESULTS: Randomized participants who received study vaccination (N = 1128; coadministration group, n = 564; separate-administration group, n = 564) had a median age of 39 years. Model-adjusted GMRs for coadministration to separate administration were 0.83 (95% CI 0.77, 0.89) for full-length S-binding IgG levels and 0.89-1.00 (lower bound of all 95% CIs > 0.67) for the four influenza strain-specific HAI titers, with all endpoints achieving the prespecified noninferiority criterion. Reactogenicity events were mostly mild or moderate when BNT162b2 was coadministered with SIIV. Serious AEs were reported in < 1% of participants within 1 month after any vaccination; none were considered vaccine-related | ||
| 520 | |a CONCLUSIONS: BNT162b2 coadministered with SIIV elicited immune responses that were noninferior to those elicited by BNT162b2 alone and SIIV alone, and BNT162b2 had an acceptable safety profile when coadministered with SIIV. The results of this study support the coadministration of BNT162b2 and SIIV in adults | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT05310084 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Coadministration | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Seasonal inactivated influenza vaccine | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Quan, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Baber, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Agnes W Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David |e verfasserin |4 aut | |
| 700 | 1 | |a Koury, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Lockhart, Stephen P |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Annaliesa S |e verfasserin |4 aut | |
| 700 | 1 | |a Türeci, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Kena A |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, William C |e verfasserin |4 aut | |
| 700 | 1 | |a Kitchin, Nicholas |e verfasserin |4 aut | |
| 700 | 0 | |a C4591030 Clinical Trial Group |e verfasserin |4 aut | |
| 700 | 1 | |a Arya, Mark |e investigator |4 oth | |
| 700 | 1 | |a Athan, Eugene |e investigator |4 oth | |
| 700 | 1 | |a Blackmore, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Bull, Sheetal |e investigator |4 oth | |
| 700 | 1 | |a Edwards, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Esquilant, Emma |e investigator |4 oth | |
| 700 | 1 | |a Finlay, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Hamilton, Paul |e investigator |4 oth | |
| 700 | 1 | |a Hemi, Tiwini |e investigator |4 oth | |
| 700 | 1 | |a Humphrey, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Kamerbeek, Jackie |e investigator |4 oth | |
| 700 | 1 | |a Kerr, Jane |e investigator |4 oth | |
| 700 | 1 | |a Kok, Jen |e investigator |4 oth | |
| 700 | 1 | |a McGirr, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Montgomery, Barnaby |e investigator |4 oth | |
| 700 | 1 | |a Neville, A Munro |e investigator |4 oth | |
| 700 | 1 | |a Quinn, Dean |e investigator |4 oth | |
| 700 | 1 | |a Sheahan, Davitt |e investigator |4 oth | |
| 700 | 1 | |a Smith, Susan |e investigator |4 oth | |
| 700 | 1 | |a Stubbs, Richard |e investigator |4 oth | |
| 700 | 1 | |a Tagelagi, Maelen |e investigator |4 oth | |
| 700 | 1 | |a Thurlow, Claire |e investigator |4 oth | |
| 700 | 1 | |a Williams, Michael |e investigator |4 oth | |
| 700 | 1 | |a Wojciechowska, Joanna |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 12(2023), 9 vom: 12. Sept., Seite 2241-2258 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:9 |g day:12 |g month:09 |g pages:2241-2258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-023-00863-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 9 |b 12 |c 09 |h 2241-2258 | ||